Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: A randomized, double blind, single-dose, crossover study

Respiratory Medicine

Volumn 101, Issue 4, 2007, Pages 845-849

  Jantikar, A ^a   Brashier, B ^a   Maganji, M ^a   Raghupathy, A ^a   Mahadik, P ^b   Gokhale, P ^b   Gogtay, J ^b   Salvi, S ^a  

^a Chest Research Foundation   (India)

^b CIPLA LTD   (India)

Author keywords

Asthma; Bronchodilator; Levosalbutamol; pressurized metered dose inhaler; salbutamol

Indexed keywords

BRONCHODILATING AGENT; LEVALBUTEROL; PLACEBO; SALBUTAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; POTASSIUM; STEREOISOMERISM; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 33847263458     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.02.020     Document Type: Article

References (21)

1. Dhand R., Goode M., Reid R., Fink J.B., Fahey P.J., and Tobin M.J. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 160 4 (1999) 1136-1141
2. Berger W.E. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 90 6 (2003) 583-591
3. Penn R.B., Frielle T., McCullough J.R., Aberg G., and Benovic J.L. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 14 1 (1996) 37-45
4. Handley D.A., Tinkelman D., Noonan M., Rollins T.E., Snider M.E., and Caron J. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 37 4 (2000) 319-327
5. Lotvall J., Palmqvist M., Arvidsson P., Maloney A., Ventresca G.P., and Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 108 5 (2001) 726-731
6. Nelson H.S., Bensch G., Pleskow W.W., DiSantostefano R., DeGraw S., et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 102 6 Pt 1 (1998) 943-952
7. Nelson H.S. Clinical experience with levalbuterol. J Allergy Clin Immunol 104 2 Pt 2 (1999) S77-S84
8. Nowak R. Single-isomer levalbuterol: a review of the acute data. Curr Allergy Asthma Rep 3 2 (2003) 172-178
9. Pereira A., Mendes E., Ferreira T., and Wanner A. Effect of inhaled racemic and (R)-albuterol on airway vascular smooth muscle tone in healthy and asthmatic subjects. Lung 181 4 (2003) 201-211
10. Mitra S., Ugur M., Ugur O., Goodman H.M., McCullough J.R., and Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 53 3 (1998) 347-354
11. Johansson F., Rydberg I., Aberg G., and Andersson R.G. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 14 1 (1996) 57-64
12. Fink J.B. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 45 6 (2000) 623-635
13. Cates C.C., Bara A., Crilly J.A., and Rowe B.H. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 3 (2003) CD000052
14. American Thoracic Society. Medical Section of the American Lung Association. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 147 4 (1993) 1056-1061
15. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152 3 (1995) 1107-1136
17. Baramki D., Koester J., Anderson A.J., and Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 109 3 (2002) 449-454
18. Jafarian A., Handley D.A., and Biggs D.F. Effects of RS-albuterol on the development of antigen-mediated airway hyperreactivity in guinea pigs. Clin Rev Allergy Immunol 14 1 (1996) 91-100
19. Gawchik S.M., Saccar C.L., Noonan M., Reasner D.S., and DeGraw S.S. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 103 4 (1999) 615-621
20. Milgrom H., Skoner D.P., Bensch G., Kim K.T., Claus R., and Baumgartner R.A. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 108 6 (2001) 938-945
21. Pancu D., LaFlamme M., Evans E., and Reed J. Levalbuterol is as effective as racemic albuterol in lowering serum potassium. J Emerg Med 25 1 (2003) 13-16